Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

254 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-03

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Simvastatin Plus Rifaximin in Decompensated Cirrhosis

NCT03150459

Cirrhoses, Liver

COMPLETED PHASE2

Efficacy of Simvastatin in Alcoholic Liver Fibrosis

NCT04971577

Liver Fibrosis Alcohol Abuse

RECRUITING PHASE2/PHASE3

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

NCT03654053

Cirrhosis

ACTIVE_NOT_RECRUITING PHASE3

Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding

NCT01095185

Cirrhosis Hypertension, Portal Bleeding Esophageal Varices +1 more

COMPLETED PHASE3

Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis

NCT01282398

Portal Hypertension. Liver Cirrhosis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current study was aimed at assessing whether a treatment based on combination of rifaximin and simvastatin would be effective in patients with decompensated cirrhosis to prevent ACLF development Considering that statins have been scarcely investigated in patients with decompensated cirrhosis due to a concern of potential higher liver and muscle toxicity in this population, a first LIVERHOPE\_SAFETY clinical trial (unpublished) was undergone to assess safety and toxicity of statins with decompensated cirrhosis.

As a preliminary result of the LIVERHOPE\_SAFETY clinical trial, it was concluded that the dose of Simvastatin 20mg per day plus Rifaximin is not associated to a higher risk of liver or muscle toxicity in patients with decompensated cirrhosis and simvastatin 20 mg was established for the LIVERHOPE\_EFFICACY study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhoses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phase III, multicentre, double-blind placebo-controlled, randomized clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Neither the participants nor the researchers will know which group the participants has been allocated to

Intervention Type DRUG

Placebo of Rifaximin/8 hours for 12 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simvastatin

Simvastatin 20 mg/day for 12 months

Intervention Type DRUG

Rifaximin

Rifaximin 400/8 hours for 12 months

Intervention Type DRUG

Placebo of Simvastatin

Placebo of Simvastatin once a day for 12 months

Intervention Type DRUG

Placebo of Rifaximin

Placebo of Rifaximin/8 hours for 12 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology
* Child-Pugh patients or Child-Pugh C patients (up to 12 points)
* Women of child-bearing potential must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence.

Exclusion Criteria

* Patients on treatment with statins or rifaximin up to one month before study inclusion.
* Patients with contraindications for statins or rifaximin therapy.
* Known hypersensitivity to simvastatin or rifaximin (or rifamycin derivatives).
* Patients with CK elevation of 50% or more above the upper limit of normal at study inclusion.
* Patients on treatment with potent inhibitors of CYP3A4 enzyme
* Patients on treatment with drugs with potential interactions with simvastatin
* Patients with previous history of myopathy.
* Patients with previous history of intestinal obstruction or those who are at increased risk of this complication.
* Patients with ACLF according to the criteria published by Moreau et al.
* Serum creatinine ≥2 mg/dL (176.8 μmol/L).
* Serum bilirubin\>5 mg/dL (85.5 μmol/L).
* 12\. INR ≥2.5
* Bacterial infection within 10 days before study inclusion.
* Gastrointestinal bleeding within 10 days before study inclusion.
* Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the New-Haven classification.
* Patients with active hepatocellular carcinoma or history of hepatocellular carcinoma that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.
* Patients on antiviral therapy for HCV or those who have received it within the last 6 months.
* Severe alcoholic hepatitis requiring corticosteroid therapy (Maddrey's Discriminant function ≥ 32 and/or ABIC score \> 6.7).
* Patients with active alcohol consumption of more than 21 units per week.
* HIV infection.
* Patients with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD \>2, chronic kidney disease with serum creatinine \>2mg/dL or under renal replacement therapy.
* Patients with current extra hepatic malignancies including solid tumours and hematologic disorders.
* Pregnancy or breastfeeding.
* Patients included in other clinical trials in the month before inclusion.
* Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.
* Refusal to give informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No